Condition: PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy · Sponsor: Novartis Pharmaceuticals
The purpose of this phase Ib/II study is to (a) in Phase Ib evaluate the safety, tolerability, and pharmacokinetics (PK) of AMO959 when given in combination with lutetium (177Lu) vipivotide tetraxetan (also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereafter referred to as AAA617) with an androgen receptor pathway inhibitor (ARPI) in participants with metastatic castration resistant prostate cancer (mCRPC) who have failed one prior ARPI and with or without prior taxane exposure, and (b) in Phase II evaluate the preliminary efficacy of AMO959 in combination with AAA617 and ARPI in participants with mCRPC who have failed one prior ARPI, but who have not yet been exposed to taxane treatment.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Always discuss trial participation with your own doctor first.
| VA Greater LA Healthcare System | Los Angeles, California, United States | Recruiting |
| Rio Grande Urology | El Paso, Texas, United States | Recruiting |
| Utah Intermountain Medical Center | Murray, Utah, United States | Recruiting |
| Novartis Investigative Site | Malvern, Victoria, Australia | Recruiting |
| Novartis Investigative Site | Melbourne, Victoria, Australia | Recruiting |
| Novartis Investigative Site | Murdoch, Western Australia, Australia | Recruiting |
| Novartis Investigative Site | Bordeaux, France | Recruiting |
| Novartis Investigative Site | Clermont-Ferrand, France | Recruiting |
| Novartis Investigative Site | Nantes, France | Recruiting |
| Novartis Investigative Site | Villejuif, France | Recruiting |
| Novartis Investigative Site | Dresden, Saxony, Germany | Recruiting |
| Novartis Investigative Site | Essen, Germany | Recruiting |
+ 9 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07226986